Ensign Peak Advisors, Inc Iveric Bio, Inc. Transaction History

Ensign Peak Advisors, Inc

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$26.24 - $39.63 $8.71 Million - $13.2 Million	-331,996 Reduced 64.82%	180,219 $7.09 Million
Q1 2023 May 15, 2023	BUY	$18.67 - $24.56 $112,953 - $148,588	6,050 Added 1.2%	512,215 $12.5 Million
Q4 2022 Feb 13, 2023	SELL	$17.24 - $23.95 $2.08 Million - $2.88 Million	-120,459 Reduced 19.22%	506,165 $10.8 Million
Q3 2022 Nov 14, 2022	BUY	$9.4 - $18.59 $1.75 Million - $3.46 Million	185,886 Added 42.18%	626,624 $11.2 Million
Q2 2022 Aug 12, 2022	BUY	$9.12 - $18.9 $2.12 Million - $4.4 Million	232,806 Added 111.96%	440,738 $4.24 Million
Q1 2022 May 16, 2022	BUY	$12.15 - $16.83 $841,302 - $1.17 Million	69,243 Added 49.93%	207,932 $3.5 Million
Q4 2021 Feb 11, 2022	BUY	$13.83 - $18.78 $717,666 - $974,531	51,892 Added 59.79%	138,689 $2.32 Million
Q3 2021 Nov 12, 2021	BUY	$7.07 - $17.5 $613,654 - $1.52 Million	86,797 New	86,797 $1.41 Million

250K

40K

Ticker ISEE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 118,078,000
Description
IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 cl...

Get notified when there are updates to the investment portfolio of Ensign Peak Advisors, Inc, based on Form 13F filings with the SEC.

Stay updated on Ensign Peak Advisors, Inc with notifications on news.